Search results
Piper Sandler keeps Zscaler shares target unchanged, underscores strategic growth By Investing.com
Investing.com· 12 hours agoOn Thursday, Piper Sandler confirmed its Overweight rating on Zscaler (NASDAQ:ZS) with a steady...
Oil Field Services Firm HMH Picks JPMorgan, Piper, Evercore for IPO
Bloomberg· 2 hours agoHave a confidential tip for our reporters? HMH Holding Inc., an oil field services joint venture...
JMP Securities Reiterates Market Perform Rating for Piper Sandler Companies (NYSE:PIPR)
ETF DAILY NEWS· 23 hours agoPiper Sandler Companies (NYSE:PIPR – Get Free Report)‘s stock had its “market perform” rating...
2024 WWE Clash at the Castle predictions, card, matches, PPV preview, start time, date, location
CBS Sports· 3 hours agoWWE hosts a pay-per-view event in Scotland for the first time this Saturday when Clash at the Castle...
Ex-Goldman Sachs employee says she felt ‘violated’ during faked YouTube exec call
Courthouse News Service· 3 hours ago“Hillel, is that you?” Berardo recalled the person on the other end of the call saying. Since Piper...
Katie Piper forced to pull out of morning show for ‘unexpected medical procedure’
Daily Telegraph· 5 days agoKatie Piper has been forced to pull out of her morning show this weekend because of an “unexpected...
Piper Sandler Companies (NYSE:PIPR) Reaches New 12-Month High at $206.69
ETF DAILY NEWS· 4 days agoPiper Sandler Companies (NYSE:PIPR – Get Free Report)’s share price hit a new 52-week high during...
JPMorgan stock maintains Overweight rating with upbeat revenue outlook By Investing.com
Investing.com· 12 hours agoOn Thursday, Piper Sandler sustained its Overweight rating and $220.00 price target for JPMorgan...
Why is Katie Piper missing her Breakfast Show and when is she back?
Yahoo Celebrity UK· 2 days agoKatie Piper has had to miss her Breakfast Show. (Getty Images) Jeff Spicer via Getty Images Katie ...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 10 hours agoOn Thursday, Piper Sandler maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT)...